About Geno Germano
Geno Germano is a director at Precision Biosciences.
Form D filings name Geno Germano as CEO and director at Elucida Oncology.
Geno Germano reports to the SEC as a director or officer of 10 public companies, including Entera Bio (ENTX), Harmony Biosciences (HRMY) and Sage Therapeutics (SAGE).
Geno Germano first appears on SEC filings in 2008.
Experience
This experience comes from SEC filings. The years are when the filings name Geno Germano in the role, so the role may have started earlier or lasted longer.
PI
Precision Biosciences Inc.
Director
2020 – 2026 · Public company (DTIL)
EL
Entera Bio Ltd.
Director
2026 · Public company (ENTX)
HI
Harmony Biosciences Holdings, Inc.
Director
2026 · Public company (HRMY)
SI
Sage Therapeutics, Inc.
Director
2016 – 2025 · Public company (SAGE)
MC
Medicines Co.
Director
2017 – 2020 · Public company (MDCO)
BI
Bioverativ Inc.
Director
2017 – 2018 · Public company (BIVV)
PI
Precigen, Inc.
President
2016 · Public company (PGEN)
PI
Pfizer Inc.
Group President
2010 – 2015 · Public company (PFE)
ZI
Zoetis Inc.
Director
2013 · Public company (ZTS)
WY
Wyeth
Pres.-US Pharm. & Wom. Health
2008 – 2009 · Public company (WYE)
Key Colleagues at Startups
The people Geno Germano works with at each company, as listed on that company's latest Form D.
Elucida Oncology, Inc. · Form D/A, Aug 3, 2023
TB
Tim Boris
Director
RR
Robert Ruffolo
Director
DZ
David Zacardelli
Director
UW
Ulrich Wiesner
Director
GS
Gary Sender
Director
RE
Robert Essner
Executive officer and director
NM
Natalie MacDonald
Director